Cordycepin in its natural form. cendeced/Depositphotos
By Nick Lavars 2021 Oct 10
By using a compound derived from a Himalayan fungus and used for centuries in Chinese medicine as a jumping off point, scientists have developed a new chemotherapy drug with powerful anti-cancer effects. Doing so involved chemically altering the compound to better infiltrate cancerous cells, which proved to boost its potency by up to 40 times.
The research carried out by University of Oxford scientists in collaboration with biopharmaceutical company Nucana began with a compound called Cordycepin. This naturally-occurring nucleoside analog has been used to treat inflammatory disease and cancer for hundreds of years, but runs into several barriers that severely limit its effectiveness when deployed to tackle tumors.
This is largely because as Cordycepin enters the bloodstream, it is rapidly broken down by an enzyme called ADA. What is left then needs to be carried into cancer cells by a nucleoside transporter, and then converted into an anti-cancer metabolite called 3’-dATP. This is a lot of hoops for the humble, naturally-occurring Cordycepin to jump through and means only meager amounts wind up making it into the tumor.
Nucana looked to harness the anti-cancer potential of Cordycepin and better equip it to navigate these considerable roadblocks, through what it calls ProTide technology. This is designed specifically to address the shortcomings of nucleoside analogs. It works by attaching small chemical groups to the compound that make it more resistant to breakdown in the bloodstream, and also enables them to enter cancer cells without the help of nucleoside transporters. The upshot is far greater levels of anti-cancer metabolites are generated and activated inside tumor cells.
This enhanced form of Cordycepin is dubbed NUC-7738, and the novel chemotherapy drug was assessed through in vitro studies, demonstrating that it overcomes the resistance mechanisms that inhibit its parent compound. Tumor samples obtained from ongoing Phase I clinical trials were then used to probe its effectiveness in humans, with these experiments validating the earlier findings.
Altogether, the authors conclude NUC-7738 to have as much as 40 times the potency of the naturally-occurring Cordycepin, and has limited toxic side effects. The scientists are now continuing to assess its performance in the Phase 1 clinical trial on patients with advanced solid tumors, and are planning to follow that up with Phase 2 trials to further evaluate its clinical potential.
The research was published in the journal Clinical Cancer Research.
Source: University of Oxford–
Nick Lavars Nick has been writing and editing at New Atlas for over six years, where he has covered everything from distant space probes to self-driving cars to oddball animal science. He previously spent time at The Conversation, Mashable and The Santiago Times, earning a Masters degree in communications from Melbourne’s RMIT University along the way.
- Bicycles Powershift replaces a bike’s front derailleur with a 2-speed hub
- Health & Wellbeing Missing link between severe COVID-19 and Alzheimer’s disease discovered
- Space Ancient Martian lake and river delta clear in Perseverance photos
GET OUR NEWSLETTER
Over 220,000 people receive our email newsletter. Get your daily dose of extraordinary ideas! Register
© 2021 New Atlas
(For the source of this, and many other equally intriguing and important articles, please visit: https://newatlas.com/medical/himalayan-fungus-compound-potent-cancer-treatment/)